Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions gets up to $22.3 million BioThrax order modification from U.S. military

Neutral Impact 2 of 5 product/contract Written later

Emergent BioSolutions received a modification exercising an option period under an existing delivery order, valued at up to $22.3 million, to supply its BioThrax anthrax vaccine to the U.S. Department of War. The filing describes the award as an extension of an existing contract rather than a new financial result, and it does not report revenue, profit, or guidance changes.

Key points

  • Order valued at up to $22.3 million under an existing delivery order and IDIQ contract (W911SR24D0001)
  • First delivery valued at approximately $7.4 million, beginning this year, with remaining deliveries expected in 2027
  • Follows an August 2026 contract modification valued at approximately $24 million for CYFENDUS anthrax vaccine to BARDA

The filing

CompanyEmergent BioSolutions Inc. (EBS)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:06 PM ET
Accession number0001367644-26-000116

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.